Ablation of tumor cells in vivo by direct injection of HSV-thymidine kinase retroviral vector and ganciclovir therapy

Annals of the New York Academy of Sciences

Volumn 880, Issue , 1999, Pages 352-365

  Howard, Bradley D ^a   Kalthoff, Holger ^a   Fong, Timothy C ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CELL; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER REGRESSION; CELLULAR IMMUNITY; COLORECTAL TUMOR; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; IMMUNOCOMPETENCE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; RETROVIRUS;

ANIMALIA; HERPES; MURINAE; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0032775383     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09538.x     Document Type: Conference Paper

References (37)

1. 1. MOOLTEN, F.L. 1994. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1: 279-287.
2. 2. MÜLLEN, C.A. 1994. Metabolic suicide genes in gene therapy. Pharmacol. Ther. 63: 199-207.
3. 3. REID, R. et al. 1988. Insertion and extension of acyclic, dideoxy, and ara nucleotides by Herpes viridae, human alpha and human beta polymerases. J. Biol. Chem. 263: 3898-3904.
4. 4. MOOLTEN, F.L. 1986. Tumor chemosensitivity conferred by inserted Herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46: 5276-5281.
5. 5. MOOLTEN, F.L. 1990. Mosaicism induced by gene insertion as a means of improving chemotherapeutic selectivity. Crit. Rev. Immunol. 10: 203-233.
6. 6. FREEMAN, S.M. et al. 1993. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53: 5274-5283.
7. 7. CULVER, K.W. et al. 1992. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552.
8. 8. KOLBERG, R. 1992. Gene therapists test puzzling "bystander effect." J. Natl. Inst. Health Res. 4: 68-72.
9. 9. RAM, Z. et al. 1994. The effect of thymidine kinase transduction and GCV therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 81: 256-260.
10. 10. RAM, Z. et al. 1994. Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res. 54: 2141-2145.
11. 11. RAM, Z. et al. 1993. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53: 83-88.
12. 12. EZZEDINE, Z.T. et al. 1991. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the Herpes simplex virus thymidine kinase gene. New Biol. 3: 608-614.
13. 13. CHIOCCA, E.A. et al. 1994. Virus-mediated genetic treatment of rodent gliomas. In Gene Therapeutics: Methods and Applications of Direct Gene Transfer. J. A. Wolff, Ed.: 245-262.
14. 14. BOVIATSIS, E.J. et al. 1994. Gene transfer into experimental brain tumors by adenovirus, Herpes simplex virus and retroviral vectors. Hum. Gene Ther. 5: 183-191.
15. 15. BARBA, D. et al. 1994. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91: 4348-4352.
16. 16. TAPSCOTT, S.J. et al. 1994. Gene therapy of rat 9L glioma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci. USA 91: 8185-8189.
17. 17. DIMAIO, J.M. et al. 1994. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116(2): 205-213.
18. 18. SMYTHE, W.R. et al. 1994. Use of recombinant adenovirus to transfer the Herpes simplex virus thymidine kinase (HSV-TK) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. 54: 2055-2059.
19. 19. FREEMAN, S.M. et al. 1992. Treatment of ovarian cancer using HSV-TK gene modified vaccine - regulatory issues. Hum. Gene Ther. 3: 342-349.
20. 20. CRYSTAL, R.G. 1995. Transfer of gene to humans: early lessons and obstacles to success. Science 270: 404-410.
21. 21. The FDA Points to Consider for Somatic Cell and Gene Therapy, Cell Lines Used to Produce Biologicals, Biologicals Produced by Recombinant DNA Technology and Administration of Activated Leukocytes can be obtained from the Biologics Information Staff, Office of the Director, Center for Biologics, FDA, Bethesda, MD 20205, USA.
22. 22. Transcript of the October 25, 1993 meeting of the Vaccines Advisory Committee of the US FDA, available from the Center for Biologics, FDA, Bethesda, MD 20205, USA.
23. 23. GEORGES, R.N. et al. 1993. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 53: 1743-1746.
24. 24. VILE, R.G. et al. 1994. Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-TK gene involves an immune component. Cancer Res. 54: 6228-6234.
25. 25. LAUBE, L.S. et al. 1994. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB env/rev proteins. Hum. Gene Ther. 5: 853-862.
26. 26. IRWIN, M.S. et al. 1994. Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and non-human primates. J. Virol. 68(8): 5036-5044.
27. 27. ENQUIST, L.W. et al. 1979. Construction and characterization of a recombinant plasmid encoding the gene for the thymidine kinase of Herpes simplex type 1 virus. Gene 7: 335-342.
28. 28. WAGNER, M.S. et al. 1981. Nucleotide sequence of the thymidine kinase gene of Herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA 78: 1441-1445.
29. 29. ARMENTANO, D. et al. 1987. Effect of internal viral sequences on the utility of retroviral vectors. J. Virol. 61(5): 1647-1650.
30. 30. CHADA, S., et al. 1993. Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes. J. Virol. 67: 3409-3417.
31. 31. BURNS, J.C. et al. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient germ transfer into mammalian and non-mammalian cells. Proc. Natl. Acad. Sci. USA 90: 8033-8037.
32. 32. HOWARD, B. et al. 1994. Retrovirus-mediated gene transfer of the human γ-interferon gene: a therapy for cancer. In Gene Therapy for Neoplastic Diseases. B.E. Huber & J.S. Lazo, Eds. Ann. N. Y. Acad. Sci. 716: 167-187.
33. 33. MACGREGOR, G.R. et al. 1987. Histochemical staining of clonal mammalian cell lines expressing E. coli beta-galactosidase indicates heterogenous expression of the bacterial gene. Som. Cell Mol. Genet. 13: 253-265.
34. 34. LU, D. et al. 1994. Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors. Cancer Gene Ther. 1(4): 245-252.
35. 35. BI, W.L. et al. 1993. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-TK retroviral gene therapy. Hum. Gene Ther. 4: 725-731.
36. 36. GOLUMBEK, P.T. et al. 1992. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, non-immunogenic tumor cell vaccines. J. Immunother. 12: 224-230.
37. 37. CHEN, S.H. et al. 1995. Combination gene therapy for liver metastases of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA 92: 2577-2581.